Active Biotech AB Interim report January - March 2012
(Thomson Reuters ONE) -
* Laquinimod - submission of application for regulatory approval in the EU
planned for second half of 2012
- Phase III data presented at the Annual Meeting of the
American Academy of Neurology (AAN)
* TASQ - a Phase I investigator-sponsored clinical trial is under way
- enrolment of patients to Phase III study proceeding
according to schedule
* ANYARA - Phase III trial continuing according to plan
* 57-57 - a clinical trial in systemic sclerosis/scleroderma in
progress
* ISI - project is proceeding as planned
* Net sales SEK 2.6 M (2.7)
* Operating loss SEK 100.7 M (loss: 70.9)
* Net loss SEK 99.0 M (loss: 69.3 )
* Loss per share for the period was SEK 1.44 (loss: 1.02)
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam
CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB (Corp Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
This report is also available at www.activebiotech.com
Active Biotech AB Interim report January - March 2012:
http://hugin.info/1002/R/1605995/508858.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1605995]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.04.2012 - 02:31 Uhr
Sprache: Deutsch
News-ID 1107401
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LUND
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 63 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January - March 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
